Short-term effect of growth hormone treatment in childhood leukemia survivors with growth hormone deficiency

Shin Chungwoo; Jang Min Jeong; Kim Seongkoo; Lee Jae Wook; Chung Nack-Gyun; Cho Bin; Jung Min Ho; Suh Byung-Kyu; Ahn Moon Bae

doi:10.6065/apem.2244028.014

추천

검색

자료유형: 학술저널

저자정보: Shin Chungwoo (College of Medicine The Catholic University of Korea Seoul Korea) Jang Min Jeong (College of Medicine The Catholic University of Korea Seoul Korea) Kim Seongkoo (College of Medicine The Catholic University of Korea Seoul Korea) Lee Jae Wook (College of Medicine The Catholic University of Korea Seoul Korea) Chung Nack-Gyun (College of Medicine The Catholic University of Korea Seoul Korea) Cho Bin (College of Medicine The Catholic University of Korea Seoul Korea) Jung Min Ho (College of Medicine The Catholic University of Korea Seoul Korea) Suh Byung-Kyu (College of Medicine The Catholic University of Korea Seoul Korea) Ahn Moon Bae (College of Medicine The Catholic University of Korea Seoul Korea)

저널정보: 대한소아내분비학회 Annals of Pediatirc Endocrinology & Metabolism Annals of Pediatric Endocrinology & Metabolism 제28권 제2호

발행연도: 2023.6

수록면: 116 - 123 (8page)

DOI: 10.6065/apem.2244028.014

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Survivors of childhood leukemia are at risk of growth impairment due to intensive chemotherapy and radiation treatments. This study investigated the auxological and biochemical characteristics of childhood leukemia survivors diagnosed with growth hormone deficiency (GHD) and the changes in these parameters after 1 year of growth hormone (GH) treatment. Methods: A total of 24 children diagnosed with GHD after leukemia treatment was analyzed. Clinical and biochemical data were collected retrospectively at leukemia diagnosis, GHD diagnosis, and 1 year after GH treatment. Standard deviation score (SDS) was calculated based on the age- and gender-adjusted population. Results: Of the 24 children included in this study, 19 received GH treatment. The median age at GHD diagnosis was 12.3 years, and the median delay in bone age was 1.46 years. Height SDS decreased from -0.69 at leukemia diagnosis to -2.58 at GHD diagnosis (P<0.001). The change in height SDS with and without GH for 1 year was 0.35 and -0.21, respectively (P=0.044). In regression analyses, higher height SDS at GHD diagnosis and a smaller decrease of the height SDS between leukemia and GHD diagnoses were positively correlated with height SDS after GH treatment. Conclusion: GH treatment could be beneficial and safe for improving height in childhood leukemia survivors with GHD. Height SDS at GHD diagnosis and reduction of height SDS between leukemia and GHD diagnosis could be potential factors in predicting the therapeutic effects. Close auxological monitoring is recommended for any childhood leukemia survivors who experience posttreatment height decline.

#Leukemia #Growth hormone deficiency #Growth hormone treatment #Height

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!